ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

WDC Widecells Group Plc

0.285
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Widecells Group Plc LSE:WDC London Ordinary Share GB00BD060S65 ORD GBP0.0025
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.285 0.28 0.29 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

WideCells Group PLC Notice of AGM (7665F)

30/10/2018 4:25pm

UK Regulatory


Widecells (LSE:WDC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Widecells Charts.

TIDMWDC

RNS Number : 7665F

WideCells Group PLC

30 October 2018

30 October 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

Notice of Annual General Meeting

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, announces that a General Meeting ('GM') will be held on Thursday 15 November at 10:00am at the offices of Fladgate LLP, 16 Great Queen St, London WC2B 5DG. The GM has been called for the purpose of considering and, if thought fit, passing resolutions in connection with the Financing Agreement announced on 27 September 2018. A Notice of GM is being posted to shareholders today and will shortly be available to view on the company's website www.widecellsgroup.com.

**ENDS**

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 
 WideCells Group          CEO - João Andrade        Tel: +44 (0)161 
                                                          920 7953 
 Shard Capital Partners   Broker - Damon Heath & Erik    Tel: +44 (0) 20 
  LLP                      Woolgar                        7186 9950 
                         -----------------------------  ---------------- 
 St Brides Partners       PR - Isabel de Salis & Priit   Tel: +44 (0) 20 
  Limited                  Piip                           7236 1177 
                         -----------------------------  ---------------- 
 

Notes to Editors

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments both accessible and affordable. This is delivered through three divisions:

-- CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

-- WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

-- Wideacademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

Stem Cell Fast Facts:

-- Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families, because it is simple, safe and painless to collect, relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

-- Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

   --     82 illnesses can currently be treated using stem cell procedures. 

-- Despite initial collection and storage often costing no more than a few GBPthousands, actual treatment can cost in the GBPhundreds of thousands - before the development of an insurance product such as CellPlan, the treatment remained largely available only to Higher Net Worth individuals.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOAFKKDBABDDBKN

(END) Dow Jones Newswires

October 30, 2018 12:25 ET (16:25 GMT)

1 Year Widecells Chart

1 Year Widecells Chart

1 Month Widecells Chart

1 Month Widecells Chart

Your Recent History

Delayed Upgrade Clock